DE60135002D1 - Arzneizusammensetzungen enthaltend oxapenem-3-carbonsäuren - Google Patents

Arzneizusammensetzungen enthaltend oxapenem-3-carbonsäuren

Info

Publication number
DE60135002D1
DE60135002D1 DE60135002T DE60135002T DE60135002D1 DE 60135002 D1 DE60135002 D1 DE 60135002D1 DE 60135002 T DE60135002 T DE 60135002T DE 60135002 T DE60135002 T DE 60135002T DE 60135002 D1 DE60135002 D1 DE 60135002D1
Authority
DE
Germany
Prior art keywords
oxapenem
sub
carboxylic acids
compositions containing
drug compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60135002T
Other languages
English (en)
Inventor
Hans Rudolf Pfaendler
Iain Nelson Simpson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amura Ltd
Original Assignee
Amura Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP00309207A external-priority patent/EP1199077A1/de
Priority claimed from GB0105766A external-priority patent/GB0105766D0/en
Priority claimed from GB0119165A external-priority patent/GB2369358A/en
Application filed by Amura Ltd filed Critical Amura Ltd
Application granted granted Critical
Publication of DE60135002D1 publication Critical patent/DE60135002D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D503/00—Heterocyclic compounds containing 4-oxa-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxapenicillins, clavulanic acid derivatives; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
DE60135002T 2000-10-19 2001-10-11 Arzneizusammensetzungen enthaltend oxapenem-3-carbonsäuren Expired - Lifetime DE60135002D1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP00309207A EP1199077A1 (de) 2000-10-19 2000-10-19 Stabilisierte Oxapenem-3-carbonsäure enthaltende Arzneimittel durch Gefriergetrocknen mit pharmazeutischen Trägern
GB0105766A GB0105766D0 (en) 2001-03-08 2001-03-08 Orally active compounds
GB0119165A GB2369358A (en) 2000-10-19 2001-08-06 Oxapenems and pharmaceutical compositions thereof
PCT/GB2001/004527 WO2002032423A1 (en) 2000-10-19 2001-10-11 Pharmaceutical compositions containing oxapenem-3-carboxylic acids

Publications (1)

Publication Number Publication Date
DE60135002D1 true DE60135002D1 (de) 2008-09-04

Family

ID=27223564

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60135002T Expired - Lifetime DE60135002D1 (de) 2000-10-19 2001-10-11 Arzneizusammensetzungen enthaltend oxapenem-3-carbonsäuren

Country Status (18)

Country Link
US (1) US7247622B2 (de)
EP (1) EP1326607B1 (de)
JP (1) JP4283535B2 (de)
CN (1) CN1219512C (de)
AT (1) ATE401884T1 (de)
AU (2) AU9400401A (de)
BR (1) BR0114762A (de)
CA (1) CA2425314C (de)
CZ (1) CZ296089B6 (de)
DE (1) DE60135002D1 (de)
DK (1) DK1326607T3 (de)
ES (1) ES2310561T3 (de)
HK (1) HK1053793A1 (de)
HU (1) HUP0500956A3 (de)
IL (1) IL155183A0 (de)
MX (1) MXPA03003280A (de)
PL (1) PL206257B1 (de)
WO (1) WO2002032423A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0106428D0 (en) * 2001-03-15 2001-05-02 Amura Ltd Antibacterial composition
US9624334B2 (en) 2009-10-23 2017-04-18 Dow Corning Corporation Hydrophilically-modified silicone compositions
WO2013053953A1 (en) * 2011-10-14 2013-04-18 Université de Liège Method for measuring beta-lactam antibiotics

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2045236A (en) 1979-03-26 1980-10-29 Hoechst Uk Ltd Oxapenem derivatives
US4293555A (en) 1979-04-17 1981-10-06 Merck & Co., Inc. 6- and 6,6-Disubstituted-2-substituted-oxapen-2-em-3-carboxylic acids
DE3725375A1 (de) * 1987-07-31 1989-02-09 Bayer Ag Stabile oxapenem-3-carbonsaeuren
DE3833693A1 (de) * 1988-10-04 1990-04-05 Bayer Ag Stabile oxapenem-3-carbonsaeuren und ihre verwendung als ss-lactamasehemmer
DE4027928A1 (de) * 1990-09-04 1992-03-05 Bayer Ag Neue 2-tert.substituierte methyl-oxapenem-3-carbonsaeuren und -ester, verfahren zu ihrer herstellung und ihre verwendung
DE4142423A1 (de) * 1991-12-20 1993-06-24 Pfaendler Hans Rudolf ((ls)-hydroxyalkyl)oxapenem-3-carbonsaeuren und ihre verwendung als betalactamasehemmer
WO1996038450A1 (en) * 1995-05-31 1996-12-05 Microcide Pharmaceuticals, Inc. Cephalosporin antibiotics
EP1199077A1 (de) * 2000-10-19 2002-04-24 Amura Limited Stabilisierte Oxapenem-3-carbonsäure enthaltende Arzneimittel durch Gefriergetrocknen mit pharmazeutischen Trägern
GB0106428D0 (en) * 2001-03-15 2001-05-02 Amura Ltd Antibacterial composition

Also Published As

Publication number Publication date
ATE401884T1 (de) 2008-08-15
HUP0500956A2 (en) 2006-05-29
CA2425314A1 (en) 2002-04-25
CZ20031214A3 (cs) 2003-10-15
AU9400401A (en) 2002-04-29
US20040067929A1 (en) 2004-04-08
IL155183A0 (en) 2003-11-23
JP4283535B2 (ja) 2009-06-24
AU2001294004B2 (en) 2007-04-26
PL206257B1 (pl) 2010-07-30
EP1326607B1 (de) 2008-07-23
CN1469744A (zh) 2004-01-21
CA2425314C (en) 2009-04-28
US7247622B2 (en) 2007-07-24
ES2310561T3 (es) 2009-01-16
BR0114762A (pt) 2003-10-07
WO2002032423A1 (en) 2002-04-25
CZ296089B6 (cs) 2006-01-11
HUP0500956A3 (en) 2013-01-28
PL361312A1 (en) 2004-10-04
DK1326607T3 (da) 2008-11-17
CN1219512C (zh) 2005-09-21
EP1326607A1 (de) 2003-07-16
MXPA03003280A (es) 2004-12-13
JP2004511519A (ja) 2004-04-15
HK1053793A1 (en) 2003-11-07

Similar Documents

Publication Publication Date Title
DE60315265D1 (de) Stickstoffhaltige heterocyclische verbindung und arzneimittel davon
TW200510441A (en) Novel compounds
EA200100755A1 (ru) 4-оксо-1,4-дигидро-3-хинолинкарбоксамиды как антивирусные агенты
DE69820248D1 (de) Pyrrolidin-derivate die eine phospholipase-a2-hemmende wirkung haben
CY1107403T1 (el) Μια μεθοδος δια την παρασκευη υπερινδοπριλης,των αναλογων ενωσεων αυτης και των αλατων αυτων με χρησιμοποιηση ενδιαμεσων ενωσεων 2,5-διοξο-οξαζολιδινης
WO2002074726A3 (en) Aniline derivatives useful as phosphodiesterase 4 inhibitors
WO2002076918A8 (en) NF-λB INHIBITOR CONTAINING SUBSTITUTED BENZOIC ACID DERIVATIVE AS ACTIVE INGREDIENT
EA200100090A3 (ru) Новые пиперидин-4-сульфонамидные производные, способ их получения и содержащие их фармацевтические композиции
ATE550332T1 (de) 4-imidazolin-2-onverbindungen als p38-map- kinaseinhibitors
AU9025601A (en) Cephem compounds and esbl-detecting reagents containing the same
EA200101230A1 (ru) Новые ингибиторы металлопротеаз, метод их получения и содержащие их фармацевтические композиции
DE60135002D1 (de) Arzneizusammensetzungen enthaltend oxapenem-3-carbonsäuren
BRPI0411664A (pt) composição oral antiplaca aquosa estável
TR200402776T4 (tr) Nöraminik asit bileşiğinin hidratları ve bunların kristal biçimleri.
HK1064673A1 (en) Fused-polycyclic compounds
AR020629A1 (es) Una sintesis de compuestos de furano sulfonamida utiles en la sintesis de nuevos inhibidores de il-1 e intermediario.
EE05136B1 (et) Asendatud imidasopridiinhendite valmistamise meetod
EA200200682A1 (ru) Новые соединения n-бензилпиперазина, способ их получения и фармацевтические композиции, их содержащие
MXPA03011647A (es) Procedimiento de resolucion para el acido ( r ) - (-) - 2-hidroxi - 2- (2 - clorofenil) acetico.
EA200500028A1 (ru) Новые соединения 3-(4-оксо-4h-хромен-2-ил)-(1h)-хинолин-4-она, способ их получения и фармацевтические композиции, которые их содержат
FI20022159A0 (fi) Uusia farmaseuttisia yhdisteitä
CY1108381T1 (el) Φαρμακευτικες συνθεσεις που περιεχουν οξαπενεμο-3-καρβοξυλικα οξεα
EA200200379A3 (ru) Новые соединения пиримидин-4-она, способ их получения и содержащие их фармацевтические композиции
EA200501691A1 (ru) Новый промежуточный продукт для получения терапевтически активных имидазопиридинов
DK1433480T3 (da) Lægemiddel indeholdende pyrimidin-derivat

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: AMURA LTD., BABRAHAM, CAMBRIDGESHIRE, GB

8364 No opposition during term of opposition